Comparisons across centres revealed the presence of baseline differences among the six-centre samples regarding AF duration, CHA2DS2-VASc, HAS-BLED, prevalence of left atrial dilation, and compromise of left ventricular ejection fraction (Table 2 and Supplementary material online, Table S1).
| Variable . | A (n = 32) . | B (n = 100) . | C (n = 106) . | D (n = 107) . | E (n = 126) . | F (n = 389) . | P overall . |
|---|---|---|---|---|---|---|---|
| Age (years) | 57.1 ± 10.9 | 59.9 ± 10.8 | 61.2 ± 9.7 | 58.7 ± 11.7 | 58.8 ± 12.4 | 60.9 ± 10.4 | 0.088 |
| ♀, % (n) | 37.5 (12) | 34.0 (34) | 27.4 (29) | 27.1 (29) | 33.1 (42) | 29.8 (116) | 0.764 |
| BMI (kg/m2) | 27.0 ± 3.4 | 26.3 ± 4.0 | 26.7 ± 3.6 | 26.7 ± 3.7 | 26.9 ± 3.8 | 26.9 ± 4.4 | 0.098 |
| AF duration (years) | 5.0 ± 3.2 | 5.3 ± 3.7 | 4.9 ± 2.7 | 4.8 ± 2.7 | 4.9 ± 2.7 | 4.4 ± 4.4 | <0.001 |
| CHA2DS2-VASc | 1.0 ± 1.3 | 1.3 ± 1.3 | 1.8 ± 1.0 | 1.5 ± 1.6 | 0.9 ± 0.8 | 1.6 ± 1.4 | <0.001 |
| HAS-BLED | 0.3 ± 0.4 | 0.6 ± 0.7 | 1.2 ± 0.7 | 0.9 ± 0.6 | 0.7 ± 0.5 | 1.0 ± 0.9 | <0.001 |
| LA dilation (>40 mm/20 cm2), % (n) | 12.5 (4) | 11.0 (11) | 65.1 (69) | 28.0 (30) | 18.2 (22) | 52.2 (203) | <0.001 |
| LVEF <50%, % (n) | 9.4 (3) | 1.0 (1) | 5.7(6) | 7.5(8) | 8.1 (10) | 2.8 (11) | 0.032 |
| Valvular CM, % (n) | 3.1 (1) | 2.0 (2) | 6.6 (7) | 0 (0) | 3.2 (4) | 3.1 (12) | 0.136 |
| HCM, % (n) | 3.1 (1) | 0(0) | 2.8(3) | 3.7 (4) | 0.8 (1) | 1.0 (4) | 0.158 |
| Variable . | A (n = 32) . | B (n = 100) . | C (n = 106) . | D (n = 107) . | E (n = 126) . | F (n = 389) . | P overall . |
|---|---|---|---|---|---|---|---|
| Age (years) | 57.1 ± 10.9 | 59.9 ± 10.8 | 61.2 ± 9.7 | 58.7 ± 11.7 | 58.8 ± 12.4 | 60.9 ± 10.4 | 0.088 |
| ♀, % (n) | 37.5 (12) | 34.0 (34) | 27.4 (29) | 27.1 (29) | 33.1 (42) | 29.8 (116) | 0.764 |
| BMI (kg/m2) | 27.0 ± 3.4 | 26.3 ± 4.0 | 26.7 ± 3.6 | 26.7 ± 3.7 | 26.9 ± 3.8 | 26.9 ± 4.4 | 0.098 |
| AF duration (years) | 5.0 ± 3.2 | 5.3 ± 3.7 | 4.9 ± 2.7 | 4.8 ± 2.7 | 4.9 ± 2.7 | 4.4 ± 4.4 | <0.001 |
| CHA2DS2-VASc | 1.0 ± 1.3 | 1.3 ± 1.3 | 1.8 ± 1.0 | 1.5 ± 1.6 | 0.9 ± 0.8 | 1.6 ± 1.4 | <0.001 |
| HAS-BLED | 0.3 ± 0.4 | 0.6 ± 0.7 | 1.2 ± 0.7 | 0.9 ± 0.6 | 0.7 ± 0.5 | 1.0 ± 0.9 | <0.001 |
| LA dilation (>40 mm/20 cm2), % (n) | 12.5 (4) | 11.0 (11) | 65.1 (69) | 28.0 (30) | 18.2 (22) | 52.2 (203) | <0.001 |
| LVEF <50%, % (n) | 9.4 (3) | 1.0 (1) | 5.7(6) | 7.5(8) | 8.1 (10) | 2.8 (11) | 0.032 |
| Valvular CM, % (n) | 3.1 (1) | 2.0 (2) | 6.6 (7) | 0 (0) | 3.2 (4) | 3.1 (12) | 0.136 |
| HCM, % (n) | 3.1 (1) | 0(0) | 2.8(3) | 3.7 (4) | 0.8 (1) | 1.0 (4) | 0.158 |
A, B, C, D, E and F, Centres; BMI, body mass index; AF, atrial fibrillation; LA, left atrium; CM, cardiomyopathy; HCM, hypertrophic cardiomyopathy.
| Variable . | A (n = 32) . | B (n = 100) . | C (n = 106) . | D (n = 107) . | E (n = 126) . | F (n = 389) . | P overall . |
|---|---|---|---|---|---|---|---|
| Age (years) | 57.1 ± 10.9 | 59.9 ± 10.8 | 61.2 ± 9.7 | 58.7 ± 11.7 | 58.8 ± 12.4 | 60.9 ± 10.4 | 0.088 |
| ♀, % (n) | 37.5 (12) | 34.0 (34) | 27.4 (29) | 27.1 (29) | 33.1 (42) | 29.8 (116) | 0.764 |
| BMI (kg/m2) | 27.0 ± 3.4 | 26.3 ± 4.0 | 26.7 ± 3.6 | 26.7 ± 3.7 | 26.9 ± 3.8 | 26.9 ± 4.4 | 0.098 |
| AF duration (years) | 5.0 ± 3.2 | 5.3 ± 3.7 | 4.9 ± 2.7 | 4.8 ± 2.7 | 4.9 ± 2.7 | 4.4 ± 4.4 | <0.001 |
| CHA2DS2-VASc | 1.0 ± 1.3 | 1.3 ± 1.3 | 1.8 ± 1.0 | 1.5 ± 1.6 | 0.9 ± 0.8 | 1.6 ± 1.4 | <0.001 |
| HAS-BLED | 0.3 ± 0.4 | 0.6 ± 0.7 | 1.2 ± 0.7 | 0.9 ± 0.6 | 0.7 ± 0.5 | 1.0 ± 0.9 | <0.001 |
| LA dilation (>40 mm/20 cm2), % (n) | 12.5 (4) | 11.0 (11) | 65.1 (69) | 28.0 (30) | 18.2 (22) | 52.2 (203) | <0.001 |
| LVEF <50%, % (n) | 9.4 (3) | 1.0 (1) | 5.7(6) | 7.5(8) | 8.1 (10) | 2.8 (11) | 0.032 |
| Valvular CM, % (n) | 3.1 (1) | 2.0 (2) | 6.6 (7) | 0 (0) | 3.2 (4) | 3.1 (12) | 0.136 |
| HCM, % (n) | 3.1 (1) | 0(0) | 2.8(3) | 3.7 (4) | 0.8 (1) | 1.0 (4) | 0.158 |
| Variable . | A (n = 32) . | B (n = 100) . | C (n = 106) . | D (n = 107) . | E (n = 126) . | F (n = 389) . | P overall . |
|---|---|---|---|---|---|---|---|
| Age (years) | 57.1 ± 10.9 | 59.9 ± 10.8 | 61.2 ± 9.7 | 58.7 ± 11.7 | 58.8 ± 12.4 | 60.9 ± 10.4 | 0.088 |
| ♀, % (n) | 37.5 (12) | 34.0 (34) | 27.4 (29) | 27.1 (29) | 33.1 (42) | 29.8 (116) | 0.764 |
| BMI (kg/m2) | 27.0 ± 3.4 | 26.3 ± 4.0 | 26.7 ± 3.6 | 26.7 ± 3.7 | 26.9 ± 3.8 | 26.9 ± 4.4 | 0.098 |
| AF duration (years) | 5.0 ± 3.2 | 5.3 ± 3.7 | 4.9 ± 2.7 | 4.8 ± 2.7 | 4.9 ± 2.7 | 4.4 ± 4.4 | <0.001 |
| CHA2DS2-VASc | 1.0 ± 1.3 | 1.3 ± 1.3 | 1.8 ± 1.0 | 1.5 ± 1.6 | 0.9 ± 0.8 | 1.6 ± 1.4 | <0.001 |
| HAS-BLED | 0.3 ± 0.4 | 0.6 ± 0.7 | 1.2 ± 0.7 | 0.9 ± 0.6 | 0.7 ± 0.5 | 1.0 ± 0.9 | <0.001 |
| LA dilation (>40 mm/20 cm2), % (n) | 12.5 (4) | 11.0 (11) | 65.1 (69) | 28.0 (30) | 18.2 (22) | 52.2 (203) | <0.001 |
| LVEF <50%, % (n) | 9.4 (3) | 1.0 (1) | 5.7(6) | 7.5(8) | 8.1 (10) | 2.8 (11) | 0.032 |
| Valvular CM, % (n) | 3.1 (1) | 2.0 (2) | 6.6 (7) | 0 (0) | 3.2 (4) | 3.1 (12) | 0.136 |
| HCM, % (n) | 3.1 (1) | 0(0) | 2.8(3) | 3.7 (4) | 0.8 (1) | 1.0 (4) | 0.158 |
A, B, C, D, E and F, Centres; BMI, body mass index; AF, atrial fibrillation; LA, left atrium; CM, cardiomyopathy; HCM, hypertrophic cardiomyopathy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
